Vancouver, British Columbia--(Newsfile Corp. - October 9, 2018) - Sona Nanotech (CSE: SONA) is one of the latest new listing on
the Canadian Securities Exchange, having previously traded on the TSX Venture Exchange as Stockport Exploration. Halifax-based Sona
is a nano technology life sciences firm that has developed two proprietary methods for the manufacture of rod shaped gold
nanoparticles.
InvestmentPitch Media has produced a "video" which
provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Nona Nanotech" in the search
box.
Its principal business is the research and development of its proprietary technology for use in multiplex diagnostic testing
platforms that will improve performance over existing tests in the market. SONA™ Gold nanorods are manufactured using patent
pending and proprietary methods that result in high-quality nanomaterials with long shelf lives, and some significantly improved
surface properties.
Sona has two gold nanorod market ready products — Gemini, for diagnostic uses, and Omni, for medical applications — with no
major further research and development required. The company is speaking with researchers in academia and industry across the world
about commercializing its breakthrough development and plans to the market through licencing and supply agreements with leading
manufacturers and developers.
Dr Shine Xu Zhang, industrial research chair in applied nanotechnology at Cape Breton University, stated: "I am very
optimistic about the future of Sona; the gold nanorods they make are very versatile, with huge application potential in various
fields."
One of the exciting applications of gold nanorods that will potentially drive global commercialization of gold nanorod
technology will be their use as a carrier device to deliver payloads of drug molecules to cells, tissue, or organs. An example is
intractable pain, such as chronic pain or cancer-related pain, treatment and management where a nano-tool/nano-device for this
treatment consists of gold nanorods wrapped in high-density lipoproteins. Research on this topic has demonstrated the high
efficiency of the gold nanorods for delivering the pain relieving agents over other nanoparticles.
It is expected that Sona's gold nano technologies may be adapted for use in applications, as a safe and effective delivery
system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
The company closed a private placement for gross proceeds of $2,000,000 from the issuance of 8 million shares at a price of
$0.25 per share. The proceeds will be used to fund business development and for general working capital.
For more information, please visit the company's website at www.sonanano.com, contact Darren Rowes, President & CEO, at 902-442-0653 or email darren@sonanano.com.
About InvestmentPitch Media
InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story
ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing
short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com
